BrainsWay (NASDAQ:BWAY) Price Target Cut to $5.00 by Analysts at Northland Securities

BrainsWay (NASDAQ:BWAYGet Rating) had its price objective lowered by Northland Securities from $15.00 to $5.00 in a research note released on Thursday morning, The Fly reports. Northland Securities currently has an outperform rating on the stock.

Several other research analysts also recently weighed in on the stock. HC Wainwright increased their price target on shares of BrainsWay from $15.00 to $16.00 and gave the stock a buy rating in a research report on Monday, August 22nd. Raymond James decreased their price objective on shares of BrainsWay from $10.00 to $8.00 and set an outperform rating on the stock in a research report on Thursday, August 11th.

BrainsWay Trading Up 1.3 %

BWAY opened at $2.03 on Thursday. BrainsWay has a 1-year low of $1.90 and a 1-year high of $9.18. The company has a market capitalization of $33.45 million, a PE ratio of -6.33 and a beta of 1.42. The firm’s 50 day simple moving average is $3.49 and its two-hundred day simple moving average is $4.85.

Institutional Trading of BrainsWay

Several institutional investors and hedge funds have recently modified their holdings of the company. Psagot Value Holdings Ltd. Israel grew its stake in BrainsWay by 196.4% during the second quarter. Psagot Value Holdings Ltd. Israel now owns 8,300 shares of the company’s stock valued at $40,000 after acquiring an additional 5,500 shares in the last quarter. Advisor Group Holdings Inc. grew its stake in BrainsWay by 130.5% during the first quarter. Advisor Group Holdings Inc. now owns 4,552 shares of the company’s stock valued at $40,000 after acquiring an additional 2,577 shares in the last quarter. Psagot Value Holdings Ltd. Israel grew its stake in shares of BrainsWay by 95.2% in the 3rd quarter. Psagot Value Holdings Ltd. Israel now owns 16,198 shares of the company’s stock worth $58,000 after buying an additional 7,898 shares in the last quarter. Millennium Management LLC purchased a new position in shares of BrainsWay in the 2nd quarter worth $73,000. Finally, Raymond James & Associates grew its stake in shares of BrainsWay by 108.2% in the 3rd quarter. Raymond James & Associates now owns 26,231 shares of the company’s stock worth $95,000 after buying an additional 13,631 shares in the last quarter. 47.94% of the stock is currently owned by institutional investors.

BrainsWay Company Profile

(Get Rating)

Brainsway Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, Europe, Israel, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.

Further Reading

The Fly logo

Receive News & Ratings for BrainsWay Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BrainsWay and related companies with MarketBeat.com's FREE daily email newsletter.